On September 1, 2022, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of its Post-Market Drug Evaluation Program.
Currently, CADTH's Scientific Advice program offers pre-market advice on early drug development plans from a Canadian health technology assessment perspective and its Reimbursement Review program provides public drug plans with reimbursement recommendations. With this program, CADTH expands its role, establishing a network of experts that will provide federal, provincial, and territorial decision-makers with information and advice regarding the safety, effectiveness, and appropriate use of approved drugs in Canada.
A key component of the program is the CoLab Network, which will consist of experts in applied research, drug evaluation methodologies, and data analysis across Canada. The network will assist decision-makers by providing timely and targeted evidence reviews based on real-world data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
